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Abstract: 
BACKGROUND 
The efficacy of energy conservation and activity management (ECAM) for fatigue reduction and 
maintenance of functional performance has never been evaluated in adults with cancer who are 
undergoing treatment. 
 
METHODS 
A randomized clinical trial compared an ECAM intervention with a control intervention focused 
on nutrition. Individuals initiating chemotherapy, radiotherapy, or concurrent therapy for cancer 
were randomized to receive either the semistructured ECAM intervention (n = 200) or the 
control intervention (n = 196). Participants in each group participated in 3 telephone sessions 
with an oncology nurse during the first 5 weeks of treatment. Data on fatigue and limitation of 
functioning were obtained before cancer treatment and at two follow-up points that coincided 
with times of high fatigue for each type of treatment. The outcomes of interest included 
perception of fatigue and functional performance. 
 
RESULTS 
A repeated-measures analysis of covariance using the type of cancer treatment as a covariate 
revealed a significant study group–by-time interaction indicating that the ECAM group 
experienced a greater decrease in fatigue over time compared with the control group (F2,544 = 
4.5; P = 0.01). The intervention was not associated with changes in overall functional 
performance. 
 
CONCLUSIONS 
Individuals who received the ECAM intervention derived a modest but significant benefit from 
it. To achieve a more robust clinical benefit from the intervention, it may be necessary to manage 
other key symptoms in addition to fatigue. Research is needed to examine symptom clusters or 
combinations associated with negative outcomes as well as combination strategies for symptom 
management. 
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Article: 
Fatigue has been described as the most frequent and distressing problem related to cancer and its 
treatment.1–4 It is known that fatigue interferes with quality of life regardless of diagnosis, 
treatment, or prognosis.5–9 There is evidence suggesting that cancer-related fatigue (CRF) has 
profound effects on a patient's ability to function in usual roles and activities,10–12 causes 
delays in treatment,13 lingers for months or years,9, 14, 15 and may be predictive of shorter 
survival in certain cancer populations.16–18 The prevalence of this symptom as well as its 
consequences identify it as a significant problem for patients with cancer who are undergoing 
treatment. 
Although the problem of CRF has been well described, only two interventions aimed at 
managing CRF have been evaluated scientifically. Research has demonstrated that a regular 
program of sustained exercise reduced perceived fatigue in women with breast cancer and in 
individuals receiving high-dose chemotherapy (CTX).19–25 It also has been demonstrated that 
the management of anemia with recombinant human erythropoietin reduces perceived fatigue in 
patients with cancer.26–28 However, exercise is not indicated for patients with cancer who have 
bone metastases, suppressed immunity, low platelet counts, or fever.29, 30 In addition, sedentary 
individuals are unlikely to initiate and/or sustain a regular exercise program. Likewise, anemia 
management is appropriate only for individuals with low hemoglobin levels. Clearly, there is a 
need for research to identify additional approaches to the management of CRF. 
 
The most common strategies selected by patients with cancer to manage fatigue include the 
reduction of activity and increased rest.31, 32 This approach to fatigue management is based on 
the misconception that CRF is like the fatigue experienced during times of health and, thus, is 
responsive to increased rest. Because CRF is not due to over-activity, it is unlikely that patients 
with cancer will benefit from reduced activity alone. However, it is possible that rest as a means 
of conserving energy resources may enable an individual to continue participation in valued 
activities.3, 5, 28 The objective of the current research was to determine whether mastery and 
use of energy conservation and activity management (ECAM) skills is beneficial to patients with 
cancer in reducing perceived fatigue and improving perceived ability to function in usual 
activities. 
 
Energy conservation is the deliberate, planned management of an individual's personal energy 
resources to prevent their depletion. The objective of energy conservation is to balance rest and 
activity during times of high fatigue so that valued activities and goals can be maintained. Taking 
additional rest periods is one energy-conservation strategy. Other strategies include priority 
setting, delegation, pacing oneself, and planning high-energy activities at times of peak energy. 
 
Because energy conservation is a common sense activity, the Common Sense Model was used to 
guide the development and implementation of the ECAM intervention.33–35 The model 
proposes three stages of information processing regarding symptom management: representation, 
coping, and appraisal. In the representation stage, the individual gathers information to form a 
mental image of a symptom, including its identity, cause, pattern, controllability, and 
consequences. During the coping stage, the individual identifies and implements self-care 
strategies to manage the symptom. The third stage, appraisal, involves an evaluation of coping 
efforts and adjustment of coping methods and/or symptom representation based on the 
experience of symptom management. A focus group study supported the validity of the model as 
an organizing framework for understanding fatigue management in patients with cancer.36 
 
Information is essential to the development of an accurate representation or mental image of the 
problem of fatigue, and coping skills are essential in handling fatigue.37 Based on the Common 
Sense Model, information is most effective when it addresses the components of a symptom 
representation that include what the symptom is, as well as the symptom's cause, pattern, 
controllability, and anticipated consequences.38 Interventions also focus on the unique symptom 
presentation for an individual, his or her history and knowledge base, and the coping strategies 
with which he or she is familiar. Successful interventions correct faulty ideas, support new 
coping efforts, and generate new skills. 
 
Most of the research on energy-conservation interventions has been conducted on populations 
with chronic illnesses other than cancer that are characterized by fatigue.28, 39–42 These include 
rheumatoid arthritis, multiple sclerosis (MS), pulmonary diseases, chronic fatigue syndrome, and 
postpolio syndrome. A qualitative content analysis40 of fatigue in individuals with chronic 
obstructive pulmonary disease and asthma and another qualitative study of individuals with 
MS39 revealed that energy conservation was used commonly to manage fatigue in these 
populations. 
 
A limited number of studies have provided evidence that energy-conservation interventions 
benefited individuals with chronic illnesses; however, those interventions involved a 
combination of approaches; therefore, it is not possible to isolate the effect of energy 
conservation alone. In addition, those studies had small samples, and some did not have a control 
group. A 9-hour, 6-week educational program that included energy-conservation information 
resulted in greater use of ECAM behaviors in an intervention group compared with a control 
group, although there was no effect on fatigue or functional status.43 A 6-session support group 
followed by a 6-session energy-conservation course was tested in a repeated-measures design 
with 54 individuals who suffered from fatigue secondary to MS.41 The pattern of fatigue in that 
study demonstrated a larger decrease during the 6-week energy-conservation course than during 
the support group. These studies of noncancer populations provide some support for the 
usefulness of energy conservation to manage fatigue during chronic illness. 
 
 
MATERIALS AND METHODS 
Design 
In the current study, a randomized clinical trial design was used to compare the ECAM 
intervention with a control intervention that was similar in terms of time and attention. A pilot 
study demonstrated that the ECAM intervention was acceptable and feasible for patients with 
cancer.44 The study was conducted at two clinical sites: a university health science center 
(University of Utah [UU], Salt Lake City, UT) and a comprehensive cancer center (Fox Chase 
Cancer Center [FCCC], Philadelphia, PA). Individuals who were beginning CTX, radiotherapy 
(RT), or concurrent therapy for cancer were randomized to receive either the semistructured 
ECAM intervention (n = 200) or the control intervention (n = 196), which involved the 
distribution of information regarding a healthy diet. 
 
Inclusion and Exclusion Criteria 
Individuals were eligible if they were currently beginning treatment for breast, lung, colorectal, 
advanced prostate, gynecologic, or testicular cancer or lymphoma and if they planned to receive 
≥ 3 cycles of CTX, 6 weeks of RT, or concurrent RT and CTX. Any prior treatment other than 
surgery was required to have been completed at least 1 month previously. Treatment was 
intended for cure or local control, and the interventions and questionnaires had to be delivered in 
English. Individuals were excluded if their treatment plan included stem cell transplantation, 
interleukins, interferons, or tumor necrosis factor or if the individual had chronic fatigue 
syndrome. Individuals also were excluded if they were enrolled in another study that involved a 
psychoeducational intervention or if they had overt evidence of psychiatric disorder. Another 
exclusion criterion was the initiation of treatment for anemia or depression during the previous 3 
weeks, because these modifiable causes of fatigue25 may have been confounded with the effect 
of the ECAM intervention. 
 
Procedure 
The Institutional Review Board (IRB) at each study site approved the research protocol in 
accordance with federal regulations. Informed consent was obtained from all study participants. 
Upon completion of the baseline questionnaires, participants were stratified by job status 
(working vs. nonworking), type of treatment (CTX vs. RT vs. concurrent therapy), and diagnosis 
(breast cancer vs. nonbreast cancer) to ensure equivalence of the experimental and control groups 
on these factors. Participants then were randomized to receive the ECAM intervention or the 
nutritional (control) intervention. 
 
Participants in each intervention group participated in three telephone sessions with a specially 
trained oncology nurse. For patients who were receiving CTX or concurrent therapy, the 
intervention occurred during the first 3 weeks of treatment; for patients who were receiving RT, 
the intervention occurred during Weeks 3–5 of treatment. Baseline data on fatigue and limitation 
of functioning were obtained before the start of cancer therapy and at two follow-up points that 
coincided with times of high fatigue for each type of treatment. For individuals who were 
receiving cyclic CTX or concurrent therapies, follow-up questionnaires were administered 48 
hours after the second and third CTX treatments, because it is known that fatigue is elevated at 
these times.45 For individuals who were receiving RT, follow-up questionnaires were 
administered during the last week of treatment and 1 month after the completion of treatment, 
times that also are recognized as times of high fatigue.2 
 
Interventions 
The ECAM intervention was based on the tenets of the Common Sense Model.33–35 The 
intervention guided the participant through the three stages of information processing proposed 
in the model.38 Information was provided to aid in the formation of an accurate representation of 
the symptom of fatigue, guide the formulation and implementation of a plan for energy 
conservation, and appraise the effectiveness of symptom-management efforts. An interactive 
approach for intervention delivery was used that built on the individual's existing knowledge of 
energy-conservation strategies and unique responses to symptoms. A specific protocol and script 
were used, but the research nurse who delivered the intervention was trained to customize the 
protocol. For example, if the participant recognized the need to delegate activities but admitted 
difficulty doing so, then the nurse counselor would work on the problem of delegation. 
 
In the first of three telephone sessions, which addressed the representation and coping stages of 
the model, individuals received information on CRF and learned energy-conservation skills that 
would assist in its management. For homework between sessions, participants completed a daily 
journal for 1 week to monitor fatigue, sleep, rest, activity, and other symptoms. They assessed 
their activity patterns by making a list prioritizing their usual activities. The journal and priority 
list provided the basis for the second session, during which the individual was assisted in 
creating an energy-conservation plan to manage valued activities and to minimize the 
interference of fatigue (the coping stage). In the third session, the individual evaluated and 
revised the plan (the appraisal stage). The planned length of the intervention sessions was 30 
minutes each for Sessions 1 and 2 and 15 minutes for Session 3. 
 
To protect the integrity of the experimental intervention, all interventions were conducted by 
telephone with staff located at FCCC. The use of a centralized staff minimized differences in the 
application of the experimental variable. Additional safeguards included 8 hours of counselor 
training, individual case supervision for the research nurses, and an examination of nurse 
adherence to key elements of the intervention. Nurse adherence in administering the key 
elements of the interventions, which was examined on a quarterly basis for 20% of cases using 
audiotapes of the interventions, consistently was > 90%, the standard set for this study. 
 
The purpose of the control intervention was to control for the amount of time and attention 
received by the experimental group. It consisted of information on nutrition and a healthy diet. 
This content was chosen because it is of interest to patients with cancer and because it is 
somewhat relevant to fatigue but is believed to be of limited value for fatigue management 
during aggressive cancer treatment.46 Information provided in the first session included a 
discussion on maintaining a healthy diet. For homework, the participant kept a dietary record for 
24 hours. The second session consisted of a review of the dietary record and a discussion about 
vitamins. The third session consisted of a discussion about minerals and an evaluation of the 
helpfulness of the information provided. No therapeutic nutritional information or information on 
symptom management was provided during the control intervention sessions. The three sessions 
were equal to the experimental intervention in terms of the amount of time spent with the 
individual (ECAM: average total time, 78 minutes; control: average total time, 72 minutes). 
 
Measures 
Because demographic and clinical information can influence the outcome of cognitive behavioral 
studies, relevant information was abstracted from the medical record or obtained from 
participants by questionnaire. The outcomes of this study included perception of fatigue and 
functional performance. Three scales were chosen to measure unique aspects of fatigue, which 
was the central variable of this study. The Short Form of the Profile of Mood States (POMS-
SF)47 contained a five-item adjective checklist that measures fatigue intensity during the past 
week; for example, exhausted was measured on a scale ranging from 1 (“not at all”) to 5 
(“extremely”). A recent study established the validity and reliability of the fatigue scale in 
patients with cancer.45 Cronbach alpha reliability for this sample was 0.89. The Schwartz 
Cancer Fatigue Scale (SCFS)48 is a similar six-item adjective checklist with two component 
scores: Physical Fatigue and Mental Fatigue. The Physical Fatigue subscale was used (Cronbach 
alpha = 0.97). The General Fatigue Scale (GFS), which is a 7-item scale (Nail LM, Meek P, 
Barsevick A, et al. Unpublished data, 2002), was designed for the current study to capture 
fatigue impact at specific times, including fatigue today, on most days, in the past 48 hours, and 
in general. Two additional items addressed distress due to fatigue and its impact on daily 
activities (Cronbach alpha = 0.95). Evidence of validity of this scale includes sensitivity to 
change in activity levels (P < 0.001) and a factor analysis demonstrating a single factor.49 
 
Limitation of functioning in valued activities due to CRF was measured using the Functional 
Performance Inventory (FPI),50 a 65-item scale with 6 subscales, including body care, 
household maintenance, physical exercise, recreation, spiritual activities, and social activities. 
Rating of items such as “going to sporting events or concerts” included “doing with no, some, or 
much difficulty” and “do not do so for health reasons.” Higher scores reflected better 
functioning. Reliability and validity have been demonstrated (Cronbach alpha for this sample = 
0.91).51, 52 
 
 
RESULTS 
Six hundred twenty-five individuals met the eligibility criteria to participate in the randomized 
clinical trial. Two hundred twenty-nine of these individuals did not enroll in the study. Reasons 
for not enrolling included lack of interest (55%) lack of timely contact (22%), or a variety of 
other reasons (49%). Because of IRB concerns about protected health information, no 
demographic information was retained from individuals who did not enroll in the study. The 
majority of the sample was female (85%), Caucasian (91%), married (68%), and college 
educated (65%) (Table 1). Forty-four percent of the total sample received treatment with RT, 
47% received CTX, and 9% received concurrent therapy. The most common diagnoses were 
breast cancer (71%) and lung cancer (16%) (Table 2). 
 
Table 1. Patient Demographics (n = 396) 
Characteristic No. of patients (%) 
 
Age (yrs)   
 Mean ± SD 56.3 ± 12.5 
 Range 18–83 
Gender   
 Female 337 (85) 
 Male  59 (15) 
Ethnicity/race   
 Caucasian 361 (91) 
 Nonwhite  35 (9) 
Education   
 No college 125 (32) 
 College+ 257 (65) 
 Unknown  14 (3) 
Marital status   
 Married 268 (68) 
Characteristic No. of patients (%) 
 Not married 119 (30) 
 Unknown   9 (2) 
Work status   
 Working 183 (46) 
 Not working 213 (54) 
Study site   
 FCCC 245 (62) 
 UU 151 (38) 
SD: standard deviation; FCCC: Fox Chase Cancer Center (Philadelphia, PA); UU: University of 
Utah (Salt Lake City, UT). 
 
Table 2. Clinical Characteristics of the Study Population (n = 396) 
Characteristic No. of patients (%) 
 
Cancer diagnosis   
 Breast 282 (71) 
 Lung  63 (16) 
 Lymphoma  24 (6) 
 Colorectal  16 (4) 
 Genital (endometrial, ovarian, prostate, testicular)  11 (3) 
Stage (AJCC/UICC)   
 0  25 (6) 
 I 120 (30) 
Characteristic No. of patients (%) 
 II 128 (32) 
 III  75 (19) 
 IV  35 (9) 
 Unavailable  13 (4) 
Treatment   
 Chemotherapy only 184 (47) 
 Radiotherapy only 176 (44) 
 Concurrent therapy  35 (9) 
 AJCC: American Joint Committee on Cancer; UICC: International Union Against Cancer. 
Two hundred thirty-four individuals provided complete data on all 3 fatigue measures at all data 
points that were conducted; 162 individuals had missing data for at least 1 data point on at least 1 
fatigue measure. These groups were compared with regard to intervention group assignment. 
Failure to complete all fatigue measures was unrelated to intervention group assignment (chi-
square [1] = 1.6; P = 0.21). Thus, complete and incomplete cases were distributed evenly across 
both study groups. 
 
Incomplete data from participants in the two intervention groups (ECAM vs. control) did not 
differ with regard to overall symptom burden (t, 1152 = 1.5; P = 0.12), baseline GFS score (t, 
1148 = 0.65; P = 0.52), or Eastern Cooperative Oncology Group (ECOG) performance status 
(Mann–Whitney U = 3556; P = 0.35). However, without regard to intervention group 
assignment, participants who had incomplete data had higher symptom burden (t, 1384 = 4.22; P 
< 0.001) and poorer ECOG performance status compared with participants who had complete 
data (U test = 10591; P = 0.01). These findings suggest that in both intervention groups, patients 
who were in poorer health were more likely to have incomplete data. 
 
Baseline equivalence between intervention groups, study sites, and cancer treatment groups was 
examined. Intervention groups (ECAM vs. control) were compared with regard to demographic 
and clinical factors using chi-square analysis and t tests to determine whether differences 
between the groups could be attributed to extraneous factors. Of particular interest were the three 
stratification factors: diagnosis (breast cancer vs. nonbreast cancer), work status (working vs. not 
working), and treatment type (RT vs. CTX vs. concurrent therapy). Interventions groups did not 
differ with regard to any demographic or clinical factor, including diagnosis, type of cancer 
treatment, or work status. To establish the equivalence of participants from the two sites (FCCC 
vs. UU), similar analyses comparing demographic and clinical variables for the two sites were 
conducted. Several differences were noted. Participants at FCCC were more likely to be African 
American (P = 0.01), less likely to be treated with RT alone (P = 0.03), and more likely to 
receive concurrent therapy (P = 0.03). FCCC participants also tended to be slightly older (P = 
0.08) compared with UU participants (mean age, 57 years vs. 55 years, respectively). 
 
Because the type of cancer treatment may influence fatigue levels, baseline equivalence of 
fatigue for each cancer treatment group (CTX only, RT only, or concurrent therapy) also was 
examined. Individuals who were treated with RT alone were older (P < 0.001) compared with 
individuals who received concurrent therapy or CTX alone, as would be expected because of 
current standards of care. Likewise, participants who received RT alone had lower stage disease 
(P < 0.001) compared with participants in other cancer treatment groups, as expected. 
 
Age, ethnicity, and type of cancer treatment were examined as potential covariates in the 
multivariate analysis comparing the efficacy of the interventions to manage fatigue and maintain 
functional performance. Age and ethnicity were unrelated to the study outcomes at follow-up, 
indicating their unsuitability as covariates. In a one-way analysis of variance (ANOVA), type of 
cancer treatment was associated with fatigue at the second follow-up point (P < 0.001), and type 
of cancer treatment was associated with functional performance at both follow-up points (P < 
0.001). Post hoc analysis indicated that the mean scores for the RT group differed from the CTX 
and concurrent therapy groups; however, the latter two groups did not differ from one another. 
For use as a covariate, type of treatment was stratified into two groups rather than three: RT only 
versus CTX or concurrent therapy. 
 
In the second step of the analysis, a manipulation check was conducted to determine whether the 
ECAM group used more energy-conservation behaviors taught during the intervention than the 
control group. At baseline and at both follow-up data points, participants in both study groups 
completed a 17-item checklist; 9 items referred to energy-conservation strategies (delegation, 
planning, pacing, etc.), and 7 items were unrelated coping behaviors (relaxation, aromatherapy, 
etc.). A repeated-measures ANOVA revealed that the ECAM group used significantly more 
energy-conservation strategies over time compared with the control group (Table 3). There was 
no difference between the intervention groups with regard to the use of non-energy-conservation 
behaviors. These findings indicate that the ECAM intervention influenced behavior in the 
expected way: individuals who were taught energy conservation used these strategies more 
frequently than did individuals who were not taught ECAM. 
 
Table 3. Means, Standard Deviations, F Tests, and P Values for Effects 
Measure 
Mean (SD) F test (repeated-measures design) 
Baseline Follow-up 1a Follow-up 2a Cancer treatment Time Study group Study group by time 
 
ECS-A               
 ECAM 0.39 (0.25) 0.64 (0.23) 0.60 (0.26) 6.8b 82.7b 1.6 12.2b 
 Control 0.47 (0.25) 0.57 (0.28) 0.58 (0.25)         
ECS-NA               
 ECAM 0.25 (0.17) 0.27 (0.21) 0.27 (0.20) 5.8c 0.99 0.2 0.6 
 Control 0.29 (0.19) 0.31 (0.21) 0.29 (0.20)         
GFS-Total               
 ECAM 3.3 (1.8) 4.6 (2.2) 4.1 (2.2) 7.7b 55.1b 0.1 4.5b 
 Control 3.3 (1.8) 4.6 (2.0) 4.7 (2.1)         
POMS-F               
 ECAM 1.9 (0.72) 2.5 (1.1) 2.4 (1.1) 15.1b 27.4b 0.6 3.70c 
 Control 1.9 (0.76) 2.5 (1.1) 2.6 (1.2)         
SCFS-P               
 ECAM 1.8 (0.70) 2.4 (0.95) 2.3 (0.99) 17.3b 60.6b 0.23 3.1c 
 Control 1.8 (0.73) 2.4 (0.94) 2.5 (1.0)         
FPI-Total               
Measure 
Mean (SD) F test (repeated-measures design) 
Baseline Follow-up 1a Follow-up 2a Cancer treatment Time Study group Study group by time 
 ECAM 2.8 2.7 2.7 5.53c 22.0b 0.41 1.5 
 Control 2.7 2.7 2.6         
SD: standard deviation; ECS-A: Energy Conservation Strategies–Appropriate; ECS-NA: Energy 
Conservation Strategies–Not Appropriate; GFS-Total: General Fatigue Scale–Total; POMS-F: 
Profile of Mood States–Fatigue; SCFS-P: Schwartz Cancer Fatigue Scale–Physical; FPI-Total: 
Functional Performance Inventory–Total. 
a Follow-up points 1 and 2 coincided with times of high fatigue for each type of treatment. 
b P < 0.01. 
c P < 0.05. 
The final step of the analysis was to test the efficacy of the ECAM intervention using a repeated-
measures analysis of covariance with type of cancer treatment controlled in the analysis. An 
intent-to-treat analysis was conducted in which all participants were evaluated as randomized, 
regardless of whether they had completed all three intervention sessions. The SAS mixed 
procedure restricted maximum likelihood method was chosen, because the current study 
involved repeated measures that were correlated and had changes in variability due to attrition.53 
Two hypotheses were tested: compared with the control group, the group that received the 
ECAM intervention would report 1) less fatigue over time and 2) less disruption of functional 
performance over time. Because three fatigue measures were used to examine different 
dimensions of the subjective experience of fatigue, each measure was examined in a separate 
repeated-measures ANOVA using cancer treatment type entered as a covariate. The significant 
study group–by-time interaction revealed that fatigue, as measured by the GFS, the POMS-F, 
and the SCFS-Physical scales, was significantly lower over time in the ECAM group (P < 0.01, P 
< 0.05, and P < 0.05, respectively) (Table 3). Because 3 fatigue measures were used, it may be 
argued that there is need for a correction of the alpha (alpha/3 = 0.017) to guard against type 1 
error; in this case, only the analysis involving the GFS would be statistically significant. 
 
A similar analysis was conducted for the measure of functional performance (FPI-Total and each 
of the six subscales). The intervention was not associated with changes in overall functional 
performance or any of the six dimensions of functional status. Because of this incongruent result, 
we examined a single item from the GFS that described the impact of fatigue on usual activities. 
A repeated-measures ANOVA with type of treatment as a covariate revealed that the ECAM 
group had significantly less disruption of usual activities compared with the control group (P = 
0.0008). 
 
Because of the disparity in terms of gender in the study population (85% females), additional 
analyses were conducted to examine gender differences in the effects of the intervention. First, 
gender was included as an independent variable in the repeated-measures ANOVA for all 
outcomes reported in Table 3; no main effect was observed, and the two-way and three-way 
interactions of interest were not statistically significant. Second, the analyses were conducted 
separately for male and female samples. For females, all of the significant interactions listed in 
Table 3 remained significant. For males, the interactions of interest did not attain statistical 
significance. 
 
 
DISCUSSION 
The results of the current study demonstrated a statistically significant difference over time in 
favor of the ECAM group. It is challenging to determine whether this was a clinically important 
difference with respect to a phenomenon that was expected to become worse due to cancer 
treatment. The goal of the ECAM intervention was to minimize the expected rise in fatigue. The 
pattern of scores was congruent with that goal, demonstrating a mean decrease in all fatigue 
measures for the ECAM group between the first and second follow-up data points compared with 
a slight increase for the control group. At least 1 empirical study was undertaken to determine 
clinically important changes in fatigue for patients with cancer;54 however, that study's design 
allowed only for the detection of clinically important increases in fatigue 2 days after treatment. 
It is not known whether this criterion is applicable to decreases in fatigue as well. Dineen et al.55 
have indicated that the magnitude of perceived clinical significance may vary depending on the 
direction of the change. We observed that 10% more ECAM participants had improvement or no 
change in fatigue, whereas about 15% fewer ECAM participants had worsening fatigue over time 
compared with the control group. Future research should assess characteristics of responders and 
nonresponders to fatigue intervention. It also appears that development and testing of a stronger 
intervention are warranted. For example, a multifaceted intervention focusing on both fatigue 
and sleep disturbance may be indicated for this population. In addition, future research should 
address questions related to the perceived clinical usefulness of the intervention. 
 
Overall, the ECAM intervention was acceptable and well tolerated; satisfaction, as measured in a 
previous pilot feasibility study,44 indicated that most participants found that the intervention was 
credible and helpful. Findings for the manipulation check demonstrated that participants who 
were taught energy-conservation strategies learned and used them over the course of the study. 
 
The lack of a significant result with respect to the primary measure of functional performance 
was puzzling. A previous qualitative study36 indicated that patients with cancer associate fatigue 
with significant decrements in functional performance. It is noteworthy that the single item on 
the GFS was significant, whereas the detailed FPI-Total was not. One difference between the two 
measures is that the GFS item addressed functional performance related to fatigue, whereas the 
FPI considered only how functioning was affected by “your health.” It is possible that patients 
with cancer viewed the FPI items in a broader context that was influenced by factors other than 
fatigue only, in effect diluting the connection between fatigue and functional performance. 
 
There are several limitations to the study results we present here. Despite our best efforts to 
include a broad sample of cancer diagnoses, patients with breast cancer constituted the majority 
of the sample. The overrepresentation of females and patients with breast cancer limits our 
ability to generalize the results to both genders and to patients with other diagnoses. 
 
Second, a substantial number of participants had missing measures, primarily due to medical 
complications. However, despite the fact that patients with incomplete data were in poorer 
health, there is no evidence of intervention group differences for patients who had incomplete 
measures with regard to baseline fatigue, overall symptom burden, or ECOG performance status. 
Because missing data were not related to group assignment, efficacy findings were not 
confounded by the inability of patients who were in poorer health to complete the data collection 
process. 
 
The overall conclusion of the current study is that more research is needed to examine symptom 
clusters or combinations associated with negative outcomes as well as multifaceted strategies for 
symptom management.56, 57 Given et al.58 have identified the symptom pair of fatigue and pain 
as a predictor of increased symptom burden. Our own research indicates that sleep disturbance is 
a prevalent problem that is likely to interact with fatigue. Specific behavioral interventions for 
sleep management may boost the overall effectiveness of fatigue and symptom management. 
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